ArticleClinicoEconomics and outcomes research : CEOR2025
Economic Evaluation of Extended-Release Amphetamine (Dyanavel XR) Among Individuals with Attention-Deficit/Hyperactivity Disorder From a United States Societal Perspective.
Ishveen Chopra et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.